<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973021</url>
  </required_header>
  <id_info>
    <org_study_id>VSEL-ED</org_study_id>
    <nct_id>NCT03973021</nct_id>
  </id_info>
  <brief_title>Very Small Embryonic-like Stem Cells for Erectile Dysfunction</brief_title>
  <official_title>Autologous Very Small Embryonic-like Stem Cells(VSELs) for Organic Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Four-Leaf Clover HealthTech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the safety and efficacy of autologous very small embryonic-like stem
      cells(VSELs) to organic erectile dysfunction, such as those associated with metabolic
      syndrome or the treatment of prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with organic erectile dysfunction adapted to enrolled criteria, this
      study will document for the first time the safety and efficacy of underlying penile cellular
      damage.

      The safety will be evaluated by tolerance degree. The efficacy will be evaluated validated
      scores and color duplex Doppler ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this group, the patients will receive intracavernous injection of autologous VSELs. The check indexes are International Index of Erectile Function 5(IIEF-5), Erection Hardness Score(EHS) and penile vascularization assessed using color duplex Doppler ultrasound (CDDU), mainly including erectile function, stretched penile length, sexual drive, intercourse satisfaction, and overall satisfaction.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Different patients receive different numbers of cell for treatment per time</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance</measure>
    <time_frame>1-4 weeks after each injection</time_frame>
    <description>Evaluation indicators include postoperative pain at the injection site (VAS score), hematoma, abscess, or priapism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term effects on erectile function</measure>
    <time_frame>3-6 months after each injection</time_frame>
    <description>Assessment using International Index of Erectile Function 5, which is physicians global assessment to measure erectile function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term effects on erectile function</measure>
    <time_frame>12 months after final injection</time_frame>
    <description>Assessment using International Index of Erectile Function 5, which is physicians global assessment to measure erectile function</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Organic Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSEL Mini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Very small embryonic-like stem cell(VSEL)</intervention_name>
    <description>Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation</description>
    <arm_group_label>VSEL Max</arm_group_label>
    <arm_group_label>VSEL Medium</arm_group_label>
    <arm_group_label>VSEL Mini</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic and systemic changes in diseases such as diabetes and atherosclerosis or
             more localized causes such as direct injury to the penile neurovascular supply during
             prostate surgery

          -  Diagnosed as an organic erectile dysfunction by at least 2 urological surgeons

        Exclusion Criteria:

          -  Non-organic erectile dysfunction, such as psychological factors

          -  Solid cancer patients other than early prostate cancer

          -  Blood disease patients, thrombocytopenia or dysfunction, hypofibrinogenemia or
             anticoagulant therapy, long-term use of aspirin

          -  Older than 70 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jibing Chen</last_name>
    <phone>+86-18903068207</phone>
    <email>jibingchen398@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central laboratory in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jibing Chen, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erectile dysfunction</keyword>
  <keyword>very small embryonic-like stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

